CLRB Cellectar Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1279704 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-37.2%
TTM EPS YoY70.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-170.0%
ROA-116.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets24.6%
Debt / equity0.00x
Current ratio4.44x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $11.50M | $26.14M |
| SG&A expense | $11.48M | $25.64M |
| Operating income | -$22.98M | -$51.78M |
| Pretax income | -$21.79M | -$44.52M |
| Income tax | — | $66,000 |
| Net income | -$21.79M | -$44.58M |
| EBITDA | -$22.77M | -$51.49M |
| EPS (basic) | -8.35 | -36.52 |
| EPS (diluted) | -8.35 | -41.89 |
| Weighted avg. shares (diluted) | 2.61M | 1.24M |
| Balance sheet | ||
| Cash & equivalents | $13.20M | $23.29M |
| Current assets | $14.04M | $24.25M |
| PP&E, net | $549,405 | $757,121 |
| Total assets | $14.98M | $25.47M |
| Current liabilities | $4.75M | $9.39M |
| Total liabilities | $5.06M | $9.80M |
| Shareholders' equity | $8.54M | $14.29M |
| Shares outstanding | 4.24M | 1.54M |
| Cash flow statement | ||
| Operating cash flow | -$23.12M | -$47.58M |
| Capital expenditure | $5,880 | $104,195 |
| Free cash flow | -$23.12M | -$47.69M |
| Investing cash flow | -$5,880 | -$104,195 |
| Financing cash flow | $13.03M | $61.41M |
| Depreciation & amortization | $213,597 | $291,653 |
| Stock-based compensation | $2.26M | $4.27M |
Free plan shows the latest 2 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.